

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M. 8338- APAX PARTNERS / UNILABS

SECTION 1.2

Description of the concentration

1. The proposed transaction concerns the indirect acquisition by funds advised by Apax Partners LLP ("**AP**") of Unilabs Holding AB ("**Unilabs**"), through the purchase of shares in its holding company (the "**Transaction**"). AP already exercises joint control over Unilabs within the meaning of the Merger regulation so that the Transaction constitutes a passage from joint control to sole control within the meaning of Article 3(1)(b) of the Merger Regulation.
2. The areas of activity of the undertakings concerned by the notified concentration are as follows:
 - **AP** – registered in the UK, is an adviser to private equity funds investing in a range of industry sectors such as the sector of technology and telecommunications, the services sector, the healthcare sector and in the consumer sector.
 - **Unilabs** - registered in Sweden but headquartered in Switzerland, is a provider of diagnostic services, active in the provision of bio-medical testing services, medical imaging services, reproductive medicine services and drug development services in a number of European countries.
3. The Transaction concerns the sector of services provided by laboratories